2002
DOI: 10.1016/s0736-0266(01)00155-3
|View full text |Cite
|
Sign up to set email alerts
|

A novel bisphosphonate inhibits inflammatory bone resorption in a rat osteolysis model with continuous infusion of polyethylene particles

Abstract: This study examined the inhibitory effect of a new bisphosphonate (TRK-530) on wear debris-mediated bone resorption in a rat osteolysis model involving continuous infusion of high density polyethylene (HDPE) particles. TRK-530 (TRK) is a novel synthetic bispliosphonate that has been shown to decrease the level of tumor necrosis factor alpha (TNF-a) in the bone marrow of rats with adjuvant arthritis. Forty Wistar rats were randomized to two groups ( i i = 20 each). In each rat, 8 Kirsliner (K) wire was inserted… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
34
0

Year Published

2004
2004
2012
2012

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 51 publications
(35 citation statements)
references
References 31 publications
0
34
0
Order By: Relevance
“…So inhibiting osteoclastogenesis and inflammation is an important step in treating wear particles induced by osteolysis. Many efforts have been made to treat or prevent wear particle osteolysis [6,13,[21][22][23][24][25][26] . Until now, only etanercept, a TNFα receptor antagonist and bisphosphonate, has been applied in clinical situations after total joint arthroplasty [26][27][28] .…”
Section: Discussionmentioning
confidence: 99%
“…So inhibiting osteoclastogenesis and inflammation is an important step in treating wear particles induced by osteolysis. Many efforts have been made to treat or prevent wear particle osteolysis [6,13,[21][22][23][24][25][26] . Until now, only etanercept, a TNFα receptor antagonist and bisphosphonate, has been applied in clinical situations after total joint arthroplasty [26][27][28] .…”
Section: Discussionmentioning
confidence: 99%
“…A novel synthetic bisphosphonate, TRK-530, has been shown to reduce bone resorption in rats with adjuvant arthritis by inhibiting the IL-1-like activity of resident peritoneal macrophages and by decreasing the bone marrow levels of cytokine-induced neutrophil chemoattractant-1 and TNF-α. Iwase and colleagues 46 randomly assigned 40 Wistar rats to 2 groups. In each rat, a Kwire was inserted into the femur and high-density PE particles were continuously infused into the knee joint.…”
Section: Potential Therapeutic Interventionsmentioning
confidence: 99%
“…Numerous in vivo and in vitro models have been developed to investigate the interactions among macrophages and other cells, wear debris, and osteolysis [1, 3, 8, 12, 16-20, 22, 29, 30, 33, 34, 42]. Instead of pumping particles into the knee and inserting a solid wire into the femoral medullary canal, we modified the rat model of Kim et al [18,22] by implanting a hollow titanium rod in the distal part of the femur and pumping particles into the femoral bone marrow cavity directly. In this modified mouse model, polyethylene particles were infused continuously into the femur through an osmotic pump to simulate the clinical scenario more closely [25,26,31,32].…”
Section: Introductionmentioning
confidence: 99%